Theonie Anastassiadis
Fondatore presso Flagship Labs 89, Inc.
Posizioni attive di Theonie Anastassiadis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Analista di Private Equity | - | - |
Alltrna
 Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Fondatore | - | - |
| Corporate Officer/Principal | - | - | |
| Flagship Labs 89, Inc. | Fondatore | - | - |
| Presidente | - | - |
Storia della carriera di Theonie Anastassiadis
Formazione di Theonie Anastassiadis
| Haverford College | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Founder | 2 |
| Private Equity Analyst | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Alltrna
Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Health Technology |
| Flagship Labs 89, Inc. | Health Technology |
